Six new healthcare stocks began trading in December. This included four new Nasdaq listings, one TSX Venture listing, and one dual NASDAQ/TSX listing.

Below is the full list of new health stocks that began trading in December:

1. ZyVersa Therapeutics (NASDAQ: ZVSA) completed a SPAC merger with Larkspur Health Acquisition Corp. on December 12.

The company has developed two proprietary product platforms with the help of top tier research scientists at the University of Miami Miller School of Medicine. Its focus is on developing products to address unmet medical needs in the fields of renal and inflammatory diseases.

The company’s lead candidate in the pipeline is a novel cholesterol efflux mediator called VAR 200, which is in Phase 2a clinical trials and is intended to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

VAR 200 has the potential to remove excess cholesterol and lipids from the kidneys, reducing structural damage and potentially reducing proteinuria and delaying disease progression in FSGS and other glomerular diseases such as Alport syndrome and diabetic kidney disease.

The company also believes that VAR 200 may be effective in treating other glomerular diseases, such as Alport syndrome and diabetic kidney disease.

ZyVers’as pipeline also includes IC 100, a unique inflammasome ASC inhibitor being developed to treat various inflammatory diseases.

Shares of ZyVersa Therapeutics trade on the NASDAQ under the ticker symbol ZVSA. For more information visit www.zyversa.com.

2. Kineta (NASDAQ: KA) completed a reverse merger with Yumanity Therapeutics and began trading on December 19.

The company plans to continue with clinical development of KVA12123, an expected differentiated VISTA blocking immunotherapy designed to address the issue of immunosuppression in the tumor microenvironment.

A Phase 1/Phase 2 clinical trial evaluating KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors will begin enrolling patients in January 2023.

The company is also working on an anti-CD27 agonist immunotherapy to address the issue of exhausted T cells and is planning to submit an Investigational New Drug (IND) application in the first half of 2024.

Kineta trades on the NASDAQ under the symbol KA. For more information visit www.kinetabio.com.

3. Shares of Lipella Pharmaceuticals (NASDAQ: LIPO) began trading on December 22 after the company completed a $7 million initial public offering at $5.75 per share.

Lipella is a clinical-stage biotechnology company creating new drugs by reformulating the active ingredients in existing generic drugs and optimizing these reformulations for new uses.

The company believes that this approach combines the cost-efficiency and risk reduction of using existing generic drugs with the potential for patent protection on their proprietary formulations.  This strategy allows Lipella to accelerate, protect, and monetize their product candidates.

The company also focuses on developing therapies for diseases that have high levels of unaddressed morbidity and mortality and for which no approved drug therapies currently exist. It says that the focus can potentially reduce the cost, time, and risk involved in obtaining marketing approval for their products.

Shares of Lipella Pharmaceuticals trade on the NASDAQ under the symbol LIPO. For more information visit www.lipella.com.

4. IMV (NASDAQ: IMV) began trading in the U.S. on the NASDAQ as well as in Canada on the Toronto Stock Exchange on December 13.

Shortly thereafter the company announced initial patient data from its ongoing VITALIZE Phase 2B trial evaluating its lead DPX product.

The VITALIZE Phase 2B trial is a randomized, parallel group study that aims to evaluate the effectiveness of IMV's lead candidate, MVP-S, in combination with pembrolizumab and cyclophosphamide in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who have received at least two previous lines of systemic therapy and are ineligible or have failed autologous stem cell transplant (ASCT) or CAR-T therapy.

The company says that the study will enroll up to 102 subjects and be conducted in two stages.

The primary endpoint of the study is the objective response rate (ORR), which will be evaluated centrally according to the Lugano (2014) criteria and measured by the number of subjects in each treatment arm who achieve a partial or complete response (PR+CR) during the two-year treatment period.

The study will also explore cell-mediated immune response, tumor immune cell infiltration, and other biomarker analyses as exploratory endpoints. All subjects will have their PD-L1 expression evaluated at baseline.

IMV trades on both the NASDAQ and TSX exchanges under the ticker symbol IMV. For more information visit www.imv-inc.com.

5. Shares of ProSomnus (NASDAQ: OSA) began trading in early December after completing a SPAC merger with Lakeshore Acquisition Corp.

The company is a manufacturer of precision, mass-customized Precision Oral Appliance Therapy devices to treat obstructive sleep apnea (OSA).

OSA is a condition in which the airway collapses repeatedly during sleep, causing oxygen shortages and abrupt awakenings with gasping or choking.

In addition to causing daytime sleepiness, OSA is linked to serious comorbidities such as heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes.

People with untreated OSA are at a higher risk of suffering a heart attack and having a stroke compared to those without the condition. It is estimated that over one billion people worldwide and 74 million people in North America have OSA, with approximately 56 million of those in North America being undiagnosed.

The company says it will use the newly raised capital to scale up its business and has plans to open a new design and manufacturing facility, which it says will be optimized for mass-customized manufacturing, AI-driven design and 3D robotic milling.

Shares of ProSomnus trade on the NASDAQ under the symbol OSA. For more information visit www.prosomnus.com.

6. Hydreight Technologies (TSX.V: NURS) began trading on the TSX Venture exchange in Canada in early  December.

The company operates a telehealth platform and medical network that it says bridges the gap between provider compliance and patient convenience.

The network offers medical director oversight, liability insurance, HIPAA-compliant documentation, access to a digital pharmacy, and more. Platform features include a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and patient management.

Hydreight released an updated version of its mobile wellness app in late December. Updates included an improved a booking experience, enhanced onboarding support and in-app training.

Shares of Hydreight Technologies trade in Canada on the TSX Venture Exchange under the symbol NURS. For more information visit www.hydreight.com.

For a complete list of past and upcoming health IPOs visit https://healthstockshub.com/news/ipo-new-listings.